AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20052721
Drug: 96-hour infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96-hour infusion of paclitaxel at a dose of 140 mg/m² iv every 21 days
Trial: 9725480
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 50% drug in core and 180 mg HPMC in coat
Trial: 9725480
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 67% drug in core and 180 mg HPMC in coat
Trial: 9725480
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 80% drug in core and 180 mg HPMC in coat
Trial: 9725480
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with whole dose in core
Trial: 9725480
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with doubled amount of HPMC in coat
Trial: 8040738
Drug: Intranasal sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sedation (INS) with 0.5% midazolam
Trial: 8040738
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous sedation (BIVS) with 1 mg midazolam as needed
Trial: 28987658
Drug: Adipose-derived stromal
RxNorm normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-derived stromal vascular fraction injection
Trial: 21487089
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (pravastatin 40 mg)
Trial: 12510818
Drug: Moderate-impact exercise
RxNorm normalized name: IMPACT
DrugBank: Topramezone (DB14826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-impact exercise with calcium supplementation (434 ± 19 mg/day)
Trial: 12510818
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (434 ± 19 mg/day) without exercise
Trial: 3780897
Drug: FET with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FET with PD during treatment sessions
Trial: 29315686
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with l-carnitine, acetyl-l-carnitine and other micronutrients for 6 months
Trial: 20018320
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection at a concentration of 10 U/ml to 3 locations around the ureteral orifice
Trial: 15259473
Drug: Artesunate (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (8 mg/kg for 3 days)
Trial: 15259473
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg for 3 days)
Trial: 8560661
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (laser therapy and TURP)
Trial: 31394994
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) only
Trial: 19680234
Drug: Extra high-catechin
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extra high-catechin GT3 (886 mg catechins, 198 mg caffeine/day)
Trial: 19680234
Drug: High-catechin GT2
RxNorm normalized name: (+)-catechin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-catechin GT2 (468 mg catechins, 126 mg caffeine/day)
Trial: 19680234
Drug: High-catechin GT1
RxNorm normalized name: (+)-catechin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-catechin GT1 (458 mg catechins, 104 mg caffeine/day)
Trial: 19680234
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink (30 mg catechins, 10 mg caffeine/day)
Trial: 18931242
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine followed by 0.5% bupivacaine (L/B)
Trial: 17433897
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors for venous thrombosis including age, surgery, hospitalization, immobility, trauma, pregnancy, hormone use, cancer, obesity, and hypercoagulation disorders.
Trial: 10928462
Drug: Antibody against
RxNorm normalized name: recombinant human IgG4 monoclonal antibody against FGF19
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody against factor XI
Trial: 9496216
Drug: i.v. thiopentone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. thiopentone combined with i.m. lignocaine (3.0 mg kg‐1)
Trial: 9496216
Drug: i.v. thiopentone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. thiopentone combined with i.m. bupivacaine (1.0 mg kg‐1)
Trial: 3529971
Drug: timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol 0.5% plus dipivefrin 0.1% twice daily given ten minutes apart
Trial: 3529971
Drug: timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol 0.5% plus dipivefrin 0.1% given twice daily four hours apart
Trial: 23591634
Drug: High-sensitivity C-reactive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity C-reactive protein, interleukin 6, receptor activator of nuclear factor κB ligand
Trial: 21673183
Drug: PE-formula (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE-formula (3.1 ± 0.3 g protein/kg/24 h, 119 ± 25 kcal/kg/24 h)
Trial: 21673183
Drug: S-formula (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-formula (1.7 ± 0.2 g protein/kg/24 h, 84 ± 15 kcal/kg/24 h)
Trial: 19922880
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg (1 tablet) alone
Trial: 19922880
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg (1 tablet) plus probucol 500 mg (2 tablets)
Trial: 19922880
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg (1 tablet) alone
Trial: 19922880
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg (1 tablet) plus cilostazol 100 mg (1 tablet)
Trial: 17070169
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus warfarin
Trial: 17070169
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus ximelagatran
Trial: 8452163
Drug: Low-dose fleroxacin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fleroxacin (200 mg once daily)
Trial: 8452163
Drug: High-dose fleroxacin
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fleroxacin (400 mg once daily)
Trial: 26163338
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry concentrate (30 mL)
Trial: 26163338
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry concentrate (60 mL)
Trial: 26163338
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PCA and VA
Trial: 25134285
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (400 ug, 6 and 12 hours prior to surgery)
Trial: 25134285
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol (400 ug, 6 and 12 hours prior to surgery)
Trial: 22915652
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg on day 3 and 80 mg per day on days 4 through 7
Trial: 9514186
Drug: MDL 100,240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 100,240 (doses: 1.56 mg, 6.25 mg, 25 mg, 3.13 mg, 12.5 mg, 50 mg)
Trial: 9514186
Drug: MDL 100,240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 100,240 (doses: 3.125 mg, 25 mg, 50 mg)
Trial: 31843995
Drug: SUL-DUR (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUL-DUR (1 g/1 g intravenously every 6 hours for 7 days)
Trial: 31843995
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous every 6 hours for 7 days)
Trial: 31843995
Drug: SUL-DUR with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUL-DUR with IMI background therapy
Trial: 16354458
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (ccHRT; Indivina, Orion Pharma, Finland)
Trial: 10644486
Drug: Rectal pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal pacing with 5-mA amplitude and 200-ms pulse width
Trial: 10644486
Drug: Rectal pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal pacing in study group
Trial: 6398158
Drug: Clozic (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozic (100 mg/day)
Trial: 6398158
Drug: Clozic (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozic (300 mg/day)
Trial: 6398158
Drug: D-penicillamine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (500 mg/day)
Trial: 6398158
Drug: Aspirin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (up to 3.6 g/day)
Trial: 30350779
Drug: Community-wide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide treatment (CWT) for 4 years
Trial: 30350779
Drug: School-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based treatment (SBT) for 2 years followed by 2 years without treatment (holiday)
Trial: 30350779
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of SBT combined with 2 years of treatment holiday
Trial: 26761518
Drug: Low-dose IL-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose IL-12 (50 μg) with HIV MAG pDNA by IM-EP
Trial: 26761518
Drug: Any vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any vaccine arm
Trial: 22508813
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg two times per day)
Trial: 15970809
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate therapy until the onset of diuresis (urine output >100 mL/hr for 2 consecutive hours)
Trial: 15970809
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate therapy for 24 hours (control group)
Trial: 11552905
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg)
Trial: 11552905
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg) plus bedtime H2-blocker
Trial: 11552905
Drug: Bedtime H2RA
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime H2RA added to proton pump inhibitor b.d.
Trial: 9314118
Drug: Lamivudine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (5 to 600 mg per day) for 4 weeks
Trial: 8365298
Drug: albuterol by
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albuterol by metered dose inhaler (0.4 mg)
Trial: 8365298
Drug: albuterol by
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albuterol by wet nebulizer (2.5 mg)
Trial: 3076999
Drug: RE7 (rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RE7 (rifampicin and ethambutol daily)
Trial: 3076999
Drug: RE3 (rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RE3 (rifampicin and ethambutol thrice weekly)
Trial: 21659893
Drug: β-alanine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-alanine (4 g·d in powdered capsule form)
Trial: 18076750
Drug: Concurrent smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent smoking cessation treatment
Trial: 18076750
Drug: Delayed smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed smoking cessation treatment
Trial: 15228924
Drug: Intravenous heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heroin treatment
Trial: 3456079
Drug: Methotrexate (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (1000 mg per square meter) infused over 24 hours
Trial: 16968848
Drug: Losartan-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan-based treatment regimen
Trial: 16968848
Drug: Atenolol-based treatment
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol-based treatment regimen
Trial: 12543279
Drug: Dawn-dusk simulation
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dawn-dusk simulation (DDS) light therapy
Trial: 11239099
Drug: Outpatient commitment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient commitment with case management services and outpatient treatment
Trial: 11239099
Drug: Sustained outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained outpatient commitment combined with intensive outpatient treatment
Trial: 2906346
Drug: Triphasic combination
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic combination of gestodene and ethinyl estradiol
Trial: 2906346
Drug: Low-dose triphasic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose triphasic combination of levonorgestrel and ethinyl estradiol
Trial: 31771942
Drug: Aquamin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquamin (800 mg of calcium per day)
Trial: 23159276
Drug: fesoterodine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fesoterodine (4 mg daily for 4 weeks with an optional increase to 8 mg)
Trial: 21385509
Drug: Resveratrol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (2 x 5 mg orally)
Trial: 18171453
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg methylphenidate, parent training programme
Trial: 18171453
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg methylphenidate, parent support programme
Trial: 18171453
Drug: placebo medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication, parent training
Trial: 18171453
Drug: placebo medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication, parent support
Trial: 14629104
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with sodium porfimer administered 48 hours before photoradiation.
Trial: 6134535
Drug: Vecuronium 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.03 mg kg‐1
Trial: 6134535
Drug: Pancuronium 0.042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.042 mg kg‐1
Trial: 31820032
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) in ICUs with low prevalence of antibiotic resistance
Trial: 31820032
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) in ICUs with moderate-to-high prevalence of antibiotic resistance
Trial: 30545718
Drug: Classic carotid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic carotid endarterectomy with xenopericardial patch closure
Trial: 25738786
Drug: Standard method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard method of warming (heat-retaining caps, warmed intravenous and irrigation fluids, and warmed blankets)
Trial: 23939292
Drug: Lotrafilcon B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafilcon B silicone hydrogel lenses (daily wear, monthly replacement)
Trial: 17237662
Drug: IA CRH
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA CRH (10 microg) + naloxone (0.12 mg)
Trial: 15566918
Drug: Azithromycin therapy
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin therapy
Trial: 8659195
Drug: Running or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running or swimming therapy (according to the stamina principle)
Trial: 8659195
Drug: Nifedipine therapy
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine therapy (40‐60 mg/d)
Trial: 2258250
Drug: Droxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxicam (20 mg/day)
Trial: 29685813
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TOBI 300 mg)
Trial: 27987240
Drug: Dapagliflozin 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5/10 mg
Trial: 24691799
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg and Fenofibrate 145 mg (simultaneous dosing)
Trial: 24691799
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg and Fenofibrate 145 mg (staggered dosing)
Trial: 22978099
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy using lymphocytes of spouses (Control)
Trial: 15604959
Drug: Early lymphoscintigraphy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early lymphoscintigraphy (15 minutes to 4 hours after radionuclide injection)
Trial: 15604959
Drug: Delayed lymphoscintigraphy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed lymphoscintigraphy (18‐24 hours after radionuclide injection)
Trial: 18452257
Drug: Lowering the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering the fasting plasma glucose (FPG) criteria for IFG from 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL)
Trial: 18452257
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with IFG (5.6‐7.0 mmol/L)
Trial: 15845691
Drug: DM-TEA (Dextromethorphan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DM-TEA (Dextromethorphan 40 mg IM combined with TEA)
Trial: 15845691
Drug: CPM-TEA (Chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM-TEA (Chlorpheniramine maleate 20 mg combined with TEA)
Trial: 15845691
Drug: CPM-GA (Chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM-GA (Chlorpheniramine maleate 20 mg with general anesthesia)
Trial: 12425755
Drug: G‐CSF 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 5 microg/kg subcutaneously daily
Trial: 12425755
Drug: leridistim 5
RxNorm normalized name: Leridistim
DrugBank: Leridistim (DB15095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leridistim 5 microg/kg subcutaneously daily
Trial: 10509850
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 (0.8% polymer concentration)
Trial: 6140700
Drug: DL‐308 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL‐308 (10 mg)
Trial: 6140700
Drug: DL‐308 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL‐308 (20 mg)
Trial: 1106447
Drug: oxazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxazepam (30 mg)
Trial: 29800026
Drug: Sirolimus gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus gel, 0.2%
Trial: 26999197
Drug: Control (Sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Sugar solution)
Trial: 23878109
Drug: Scutellaria lateriflora
RxNorm normalized name: Scutellaria lateriflora
DrugBank: Scutellaria lateriflora (DB14339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scutellaria lateriflora (350 mg) three times daily for two weeks